Any current/future new fundraising through debt or equity?

Currently, Supriya Lifescience Limited is following a conservative borrowing approach, primarily using letters of credit and bank guarantees without tapping into working capital limits. For the current year, CAPEX plans are focused on completing module E and the Ambernath facility, with about Rs. 100 crore planned for repairs of modules A, B, and C over phases. There is no immediate indication of new debt or equity fundraising planned; next major expansion at Patalganga is considered 2.5 to 3 years down the line. No mention of any new fundraising through equity or debt in the near term during

Any current/future capex/capital investment/strategic investment?

Current year CAPEX focuses on completing Module E and Ambernath facility. Planned maintenance CAPEX for existing modules A, B, and C, estimated around Rs. 100 crore over phases. No major CAPEX beyond this is anticipated in the near term. Next significant expansion wave likely in 2.5 to 3 years, targeting Patalganga site. Module E expansion adds about 400 KL capacity; Ambernath adds about 70 KL, totaling approx. 1,020 KL capacity. Commercial production from Module E began in Q3; full utilization expected by end of FY27. Operating expenses related to new facilities will increase by a few crores

Future growth expectations in sales/revenue/volumes?

Revenue expected to be higher in H2 FY25 compared to H1, with new product launches in Q3 gaining traction in non-regulated markets. Whey protein project awaiting FSSAI license, expected by end of Q3, adding to revenue. CMO/CDMO opportunities, particularly in formulation and API advanced intermediates, expected to start commercial revenue from Q4 FY25 or Q1 FY26. Ambernath formulation contract manufacturing facility to begin revenue generation from Q4 FY25 or Q1 FY26. Base case revenue target for FY27 is Rs. 1,000 crore, with potential upside to Rs. 1,200 crore due to higher utilization

Future growth expectations in earnings/operating earnings/profits/EPS?

Revenue growth guidance of +20% year-on-year, with expectations of reaching around Rs. 700 crore in the current fiscal year Target to double revenue to Rs. 1,000 crore by FY27, focusing on high-margin niche regulated markets EBITDA margins annualized expected around 32%-34%, with recent quarters showing up to 39%, indicating robust margin sustainability Absolute EBITDA and PAT values projected to see significant growth year-on-year, despite some quarter-on-quarter margin volatility CMO/CDMO business anticipated to contribute up to 20% of total revenue within 3 years New products and

Current/ Expected Orderbook/ Pending Orders?

The company expects the order book and pending orders to contribute positively, with clear visibility on several projects already in hand. Existing portfolio growth in regulated markets and new products gaining traction in semi-regulated and regulated markets are key contributors. Contract Manufacturing Organization (CMO) and Contract Development Manufacturing Organization (CDMO) opportunities on the API advanced intermediate front and formulations from the Ambernath site will add to commercial revenue starting Q4 FY25 or Q1 FY26. CMO formulation work at Ambernath will be for contract ma

Supriya Lifesci.Q2 FY25Pharmaceuticals & Biotechnology

Supriya Lifesci. Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹931P/E: 39.9Market Cap: ₹7.9K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Revenue expected to be higher in H2 FY25 compared to H1, with new product launches in Q3 gaining traction in non-regulated markets.
Whey protein project awaiting FSSAI license, expected by end of Q3, adding to revenue.
CMO/CDMO opportunities, particularly in formulation and API advanced intermediates, expected to start commercial revenue from Q4 FY25 or Q1 FY26.
Ambernath formulation contract manufacturing facility to begin revenue generation from Q4 FY25 or Q1 FY26.
Base case revenue target for FY27 is Rs. 1,000 crore, with potential upside to Rs. 1,200 crore due to higher utilization and new product traction.
New product launches expected to contribute around 15% of topline in 2 years.
Continued strong growth in regulated markets including LATAM, Europe, and North America.
Capacity expansion (Module E and Ambernath) expected to reach full utilization by end FY27, supporting 20%+ year-on-year revenue growth.

Margin guidance

Category 3

Revenue growth guidance of +20% year-on-year, with expectations of reaching around Rs. 700 crore in the current fiscal year
Target to double revenue to Rs. 1,000 crore by FY27, focusing on high-margin niche regulated markets
EBITDA margins annualized expected around 32%-34%, with recent quarters showing up to 39%, indicating robust margin sustainability
Absolute EBITDA and PAT values projected to see significant growth year-on-year, despite some quarter-on-quarter margin volatility
CMO/CDMO business anticipated to contribute up to 20% of total revenue within 3 years
New products and facility expansions (Module E, Ambernath site) expected to drive higher revenues from H2 FY25 onwards
Oral cancer detection kit and other new therapeutic products expected to contribute commercially within ~3 years, adding to future earnings growth

See what Supriya Lifesci. management said on margin guidance — free account, 30 seconds.

Fundraise plans

Currently, Supriya Lifescience Limited is following a conservative borrowing approach, primarily using letters of credit and bank guarantees without tapping into working capital limits.
For the current year, CAPEX plans are focused on completing module E and the Ambernath facility, with about Rs. 100 crore planned for repairs of modules A, B, and C over phases.
There is no immediate indication of new debt or equity fundraising planned; next major expansion at Patalganga is considered 2.5 to 3 years down the line.
No mention of any new fundraising through equity or debt in the near term during the conference.
The company seems focused on organic growth and efficient use of existing financial resources while maintaining a strong financial position with a very low debt-to-equity ratio of 0.01.

Order book

The company expects the order book and pending orders to contribute positively, with clear visibility on several projects already in hand.
Existing portfolio growth in regulated markets and new products gaining traction in semi-regulated and regulated markets are key contributors.
Contract Manufacturing Organization (CMO) and Contract Development Manufacturing Organization (CDMO) opportunities on the API advanced intermediate front and formulations from the Ambernath site will add to commercial revenue starting Q4 FY25 or Q1 FY26.
CMO formulation work at Ambernath will be for contract manufacturing only, not own label products.
Revenue and margins from these opportunities are expected to be in line with or better than current margin profiles.
The base case revenue target is ₹1,000 crore for FY27 with upside potential from higher utilization of new facilities and new products.

See what Supriya Lifesci. management said on order book — free account, 30 seconds.

Capex plans

Yes

Current year CAPEX focuses on completing Module E and Ambernath facility.
Planned maintenance CAPEX for existing modules A, B, and C, estimated around Rs. 100 crore over phases.
No major CAPEX beyond this is anticipated in the near term.
Next significant expansion wave likely in 2.5 to 3 years, targeting Patalganga site.
Module E expansion adds about 400 KL capacity; Ambernath adds about 70 KL, totaling approx. 1,020 KL capacity.
Commercial production from Module E began in Q3; full utilization expected by end of FY27.
Operating expenses related to new facilities will increase by a few crores per quarter due to staffing and power costs but offset partially by solar power savings.

Track Supriya Lifesci. — get its next earnings analysis in your feed

How does Supriya Lifesci. rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisSupriya Lifesci.

Rev 3Mar 3

See where Supriya Lifesci. sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Supriya Lifesci. rank in Pharmaceuticals & Biotechnology?

Compare Supriya Lifesci. against every Pharmaceuticals & Biotechnology company (Q2 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Supriya Lifesci.'s management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Supriya Lifesci. Q2 FY25 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Supriya Lifesci. rank in Pharmaceuticals & Biotechnology?

Continue your research

What Supriya Lifesci.'s management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season